news
New insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
List view / Grid view
Cancer
news
How fusion proteins drive paediatric cancer
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
news
RAD51 prevents DNA re-replication
Researchers find that the RAD51 protein prevents genomic duplications that could arise from reactivated origins.
article
Women in Stem with Leila Jaafar
After gaining her PhD in Biophysics as an International Max-Planck Research School scholar, Leila joined the nuclear field in 2006, starting as an engineer in radiation protection and neutron fluence. Throughout Leila’s career, she has worked across multiple disciplines as a technical project lead in nuclear engineering, lastly in the…
article
The future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
whitepaper
Beyond the lab: immuno-oncology
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
article
Unlocking the power of stem cell therapy
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
news
Integrin αV and β5 partner to drive cancer cell growth
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
news
Augmenting cancer immunogenicity through MHC class I
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
news
Improving cancer treatment by exploiting mtDNA mutations
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
news
The potential of PD-L2 inhibitors for cancer treatment
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
article
Immuno-oncology innovations redefining cancer treatment in 2024
In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.
news
Off-switches developed for CRISPR-Cas3 technologies
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
news
Studying the effects of 3D genome organisation on gene silencing
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
news
Investigating neuron-OPC synapses in live tissue
Oligodendrocyte precursor cells and the synapses they form with neurons could be relevant to many disease conditions, including cancer.